➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
McKinsey
Johnson and Johnson
Mallinckrodt
Colorcon
McKesson

Last Updated: December 1, 2020

DrugPatentWatch Database Preview

Claims for Patent: 9,066,980

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,066,980
Title:Liquid pharmaceutical formulations of palonosetron
Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
Inventor(s): Calderari; Giorgio (Rancate, CH), Bonadeo; Daniele (Casalzuigno, IT), Cannella; Roberta (Varese, IT), Macciocchi; Alberto (Melide, CH), Miksztal; Andrew (Palo Alto, CA), Malefyt; Thomas (Carmel Valley, CA), Lee; Kathleen M (Palo Alto, CA)
Assignee: Helsinn Healthcare SA (Lugano/Pazzallo, CH) Roche Palo Alto LLC (Palo Alto, CA)
Application Number:13/902,299
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,066,980
Patent Claims: 1. A pharmaceutical single-use, unit-dose formulation for intravenous administration to a human to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising a 5 mL sterile aqueous solution, said solution comprising: a) palonosetron hydrochloride in an amount of 0.25 mg based on the weight of its free base, b) optionally a chelating agent, and c) a tonicifying agent in an amount sufficient to make said solution isotonic, wherein said formulation is stable at 24 months when stored at room temperature.

2. The pharmaceutical formulation of claim 1, wherein said solution is buffered at a pH of 5.0.+-.0.5.

3. The pharmaceutical formulation of claim 1, wherein said tonicifying agent is mannitol.

4. The pharmaceutical formulation of claim 3, wherein said mannitol is in an amount from 10 mg/mL to 80 mg/mL.

5. The pharmaceutical formulation of claim 4, wherein said mannitol is in an amount of 41.5 mg/mL.

6. The pharmaceutical formulation of claim 1, wherein said formulation comprises a chelating agent.

7. The pharmaceutical formulation of claim 6, wherein said chelating agent is EDTA.

8. The pharmaceutical formulation of claim 7, wherein said EDTA is in an amount of from 0.005 mg/mL to 1.0 mg/mL.

9. The pharmaceutical formulation of claim 8, wherein said EDTA is in an amount of 0.5 mg/mL.

10. The pharmaceutical formulation of claim 1, wherein said solution further comprises a citrate buffer.

11. The pharmaceutical formulation of claim 10, wherein said citrate buffer is at a concentration of 20 millimolar.

12. A method for reducing the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising intravenously administering to a human in need thereof the pharmaceutical formulation of claim 1, wherein said intravenous administration to said human occurs before the start of the cancer chemotherapy.

13. The method of claim 12, wherein said intravenous administration to said human occurs over a period of time of 10 to 60 seconds.

14. The method of claim 12, wherein said intravenous administration reduces the likelihood of acute nausea and vomiting in said human.

15. The method of claim 12, wherein said intravenous administration reduces the likelihood of delayed nausea and vomiting in said human.

16. A pharmaceutical single-use, unit-dose formulation for intravenous administration to a human to reduce the likelihood of cancer chemotherapy-induced nausea and vomiting, comprising a 5 mL sterile aqueous solution, said solution comprising: a) palonosetron hydrochloride in an amount of 0.25 mg based on the weight of its free base, b) optionally a chelating agent, and c) a tonicifying agent in an amount sufficient to make said solution isotonic, wherein said formulation is stable at 18 months when stored at room temperature.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
Merck
Dow
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.